For the Inventor, By the Inventor

Enter assignee name

Ontario, Canada

Syn X Pharma, Inc.

Calculating rank

USPTO Granted Patents = 33

% Expired Patents = 87.9

EPO Patents = 1

Forward Citations = 308

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

George Jackowski (32 out of 71 patents)

John G Marshall (26 out of 44 patents)

Jason Yantha (16 out of 27 patents)

4. Brad Thatcher (16 out of 22 patents)

5. Tammy Vrees (16 out of 21 patents)

6. Miyoko Takahashi (3 out of 9 patents)

7. Rulin Zhang (1 out of 2 patents)

8. Shirley Furesz (1 out of 1 patent)

9. Weimin Zhu (1 out of 2 patents)

10. Christopher Smith (1 out of 1 patent)

11. Eric B Stanton (1 out of 5 patents)

12. Michelle Davey (3 patents)

13. Peter Kupchak (3 patents)

Core Competencies:

Biopolymer Markers

Alzheimer's Disease

Insulin Resistance

Diagnostic Methods

Molecular Weight

Protein Markers

Cognitive Impairment

Disease State

Human Glutamine Synthetase

Complement C3 Precursor

Inter-alpha Trypsin Inhibitor

Amino Acid Sequence

33 patents: Sort by Forward Citations

1. 7179606 - IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease (2007-02-20),

2. 7132244 - Betaine/GABA transport protein biopolymer marker indicative of insulin resistance (2006-11-07),

3. 7101680 - Method for detecting the presence of monomeric brain associated human glutamine synthetase (2006-09-05),

4. 7097989 - Complement C3 precursor biopolymer markers predictive of type II diabetes (2006-08-29),

5. 7094549 - Fibronectin biopolymer marker indicative of insulin resistance (2006-08-22),

6. 7087435 - Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons (2006-08-08),

7. 7074576 - Protein biopolymer markers indicative of alzheimer's disease (2006-07-11),

8. 7070945 - Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment (2006-07-04),

9. 7052849 - Protein biopolymer markers predictive of insulin resistance (2006-05-30),

10. 7049397 - Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons (2006-05-23),

11. 7026129 - IG lambda biopolymer markers predictive of Alzheimers disease (2006-04-11),

12. 7015004 - Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance (2006-03-21),

13. 7014854 - Method for retarding or precluding Alzheimer's dementia (2006-03-21),

14. 6998243 - Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons (2006-02-14),

15. 6891154 - Amino acid sequence pattern matching (2005-05-10),

Company Overview

Syn X Pharma, Inc. is a biotechnology company based in Ontario, Canada, focused on the development and commercialization of innovative therapeutic solutions. The organization specializes in advanced drug delivery systems and novel pharmaceutical formulations aimed at enhancing patient outcomes. With a commitment to research and development, Syn X Pharma leverages cutting-edge technologies to address unmet medical needs across various therapeutic areas, including oncology and neurology, positioning itself as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

33 Patents

#5 in Ontario

#10,327 in Canada

#20,211 in the World

Ontario, Canada

Syn X Pharma, Inc.

Forward Citations = 308

11 inventors:

George Jackowski (32 out of 71 patents)

John G Marshall (26 out of 44 patents)

Jason Yantha (16 out of 27 patents)

4. Brad Thatcher (16 out of 22 patents)

5. Tammy Vrees (16 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Syn X Pharma, Inc.. Retrieved from https://idiyas.com/company/syn-x-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…